Avalo Therapeutics (AVTX) Payables (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Payables came in at $356000.0 in Q1 2026, down 65.8% YoY from $1.0 million in Q1 2025, and up 159.85% on a QoQ basis from $137000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Payables (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Payables data on file, last reported at $356000.0 in Q1 2026.
- Quarterly Payables fell 65.8% year-over-year to $356000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356000.0 (down 65.8% YoY) and the FY2025 annual result came in at $137000.0, down 78.69% from the prior year.
- Payables grew to $356000.0 in Q1 2026, from $137000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $14.9 million in Q2 2023 to a low of $137000.0 in Q4 2025.
- A 5-year average of $3.4 million and a median of $1.0 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables soared 586.97% — and 2024, when it plunged 95.6%.
- Tracing AVTX's Payables over 5 years: stood at $8.8 million in 2022, then sank by 94.94% to $446000.0 in 2023, then soared by 44.17% to $643000.0 in 2024, then plunged by 78.69% to $137000.0 in 2025, then jumped by 159.85% to $356000.0 in 2026.
- The last three Payables figures came in at $356000.0 (Q1 2026), $137000.0 (Q4 2025), and $474000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 3.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.35 Mn |
| Mar 31, 2026 | 356,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | 474,000.00 |
| Jun 30, 2025 | 2.74 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 643,000.00 |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 654,000.00 |
| Mar 31, 2024 | 916,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 789,000.00 |
| Jun 30, 2023 | 14.87 Mn |
| Mar 31, 2023 | 14.86 Mn |
| Dec 31, 2022 | 8.81 Mn |
| Sep 30, 2022 | 4.01 Mn |
| Jun 30, 2022 | 2.16 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 3.37 Mn |
| Sep 30, 2021 | 3.57 Mn |